Deliberate hypoxic pelvic and limb chemoperfusion in the treatment of recurrent melanoma

American Journal of Surgery

Volumn 183, Issue 1, 2002, Pages 28-36

  Guadagni, Stefano ^a   Russo, Filippo ^b   Rossi, Carlo Riccardo ^c   Pilati, Pier Luigi ^c   Miotto, Diego ^c   Fiorentini, Giammaria ^d   Deraco, Marcello ^e   Santinami, Mario ^e   Palumbo, Giancarlo ^a   Valenti, Marco ^a   Amicucci, Gianfranco ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^e NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Hypoxia; Locoregional chemotherapy; Melanoma; Melphalan; Perfusion; Stop flow

Indexed keywords

CISPLATIN; DACARBAZINE; EPIRUBICIN; MELPHALAN;

ADULT; AGED; ARTICLE; BALLOON OCCLUSION; CANCER SURGERY; CLINICAL TRIAL; DISEASE COURSE; FEMALE; HEMODYNAMICS; HUMAN; HYPOXIA; LIMB; LIMB PERFUSION; MALE; MELANOMA; PALLIATIVE THERAPY; PELVIS; PEROPERATIVE COMPLICATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SURGICAL MORTALITY; SURVIVAL RATE;

ADULT; AGED; ANOXIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CISPLATIN; DACARBAZINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; LEG; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PALLIATIVE CARE; PELVIS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 0036178729     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(01)00841-8     Document Type: Article

References (32)

1. The role of surgery in the treatment of nonregionally recurrent melanoma
2. The effect of palliative radiation therapy on epidural compression due to metastatic malignant melanoma
3. Systemic treatments for advanced cutaneous melanoma
4. Regional chemotherapy for cancer: Experiences with 116 perfusions
5. Value of perfusion in pelvic surgery
6. Intra-arterial chemotherapy with concomitant hemofiltration (chemofiltration) for treatment of locoregional or pelvic metastases from malignant melanoma
7. Preoperative therapy for advanced pelvic malignancy by isolated pelvic perfusion with the ballon-occlusion technique
8. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells
9. Effect of some proliferative and environmental factors on the toxicity of mitomycin C to tumor cells in vitro
10. Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid
11. Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats
12. Epirubicin has modest single-agent activity in head and neck cancer but limited activity in metastatic melanoma and colorectal cancer: Phase II studies by Eastern Cooperative Oncology Group
13. Hyperthermic antiblastic perfusion in the treatment of local recurrence or in transit metastases of limb melanoma
14. Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma
15. Isolated limb infusion with melphalan for recurrent melanoma: A simple alternative to isolated limb perfusion
16. Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit
17. Tourniquet infusion versus hyperthermic perfusion
18. Hypoxic isolated limb perfusion with mitomycin C in locally recurrent melanoma and sarcoma: Result of a phase II study
19. Isolated limb infusion with cytotoxic agents: A simple alternative to isolated limb perfusion
20. Pelvic stopflow infusion (PSI) and hypoxic pelvic perfusion (HPP) with mitomycin and melphalan for recurrent rectal cancer
21. Pilot study of intra-arterial cisplatin and intravenous vinblastine and dacarbazine in patients with melanoma in-transit metastases
22. Hypertermic antiblastic perfusion with DTIC in stage IIIA-IIIAB melanoma of the extremities
23. High-performance liquid chromatographic assay for melphalan in human plasma. Application to pharmacokinetic studies
24. Complications and outcome of external hemipelvectomy in the management of pelvic tumors
25. Extracorporeal hemofiltration: A model for decreasing systemic drug exposure with intra-arterial chemotherapy
26. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma
27. Differences between melphalan and nitrogen mustard in the formation and removal of DNA cross-links
28. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon-alfa, and interleukin-2 for patients with metastatic melanoma
29. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon-alfa-2B in patients with metastatic melanoma
30. Phase II trial of escalated dose of tirapazamine combined with cisplatin in advanced malignant melanoma
31. Hyperthermic pelvic isolation-perfusion in the treatment of refractory pelvic cancer